New Scientific Approaches in Fertility & Women’s Health

Infertility is a Growing Global Challenge Affecting 1 in 6 Individuals

Developing Therapeutic Solutions for Male Fertility

Improving Success Rates in Assisted Reproductive Technologies

Innovation in Women’s Health: Management of Adenomyosis

Who we are

At ReproNovo, we develop novel therapies for fertility and women’s health, focusing on areas where innovative solutions have the potential to become important additions to the treatment landscape worldwide.

Our vision

We envision becoming a leading global company committed to addressing critical gaps in fertility and women’s health. By advancing new scientific approaches, we aim to deliver innovative therapies that meaningfully expand treatment options for male and female infertility and pioneering treatment options for conditions like adenomyosis.

Our areas of focus

Fertility:

Male fertility – Inducing and increasing sperm production in infertile men with low testosterone
Female fertility – Improving embryo implantation and increasing IVF/ICSI success rates

Women’s Health:

Management of adenomyosis

Media & Meetups

All Media

July 06, 2026

REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION

Lausanne, Switzerland and Copenhagen, Denmark, July 06, 2026 – ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced that the first participant has been dosed in the Company’s EU Phase 2 clinical trial of RPN-002, entitled Nolasiban…

March 20, 2026

REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD

Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 – ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced the appointment of Mark Altmeyer as Chairman of the Board of Directors.

September 30, 2025

REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA

Lausanne, Switzerland and Copenhagen, Denmark, September 30, 2025 – ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that China’s National Medical Products Administration (NMPA) has issued a clinical trial approval notice for RPN-001 (leflutrozole). This approval…

All Meetups

We are backed by renowned international investors with deep knowledge of reproductive medicine and women’s health who share our passion to bring innovation to patients in need.